Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-04-04
|
XOMA 129 |
severe acute hypoglycemia |
preclinical |
Xoma (USA - CA) |
Metabolic diseases |
2016-04-04
|
Saxenda® (liraglutide 3 mg) |
treatment of adults with obesity or who are overweight with comorbidities |
3 |
Novo Nordisk (Denmark) |
Metabolic diseases |
2016-04-04
|
CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K |
relapsed/refractory lymphoma or multiple myeloma |
1 |
Curis (USA - MA) |
Cancer - Oncology |
2016-04-04
|
CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K |
relapsed and/or refractory diffuse large B-cell lymphoma |
2 |
Curis (USA - MA) |
Cancer - Oncology |
2016-04-01
|
romosozumab (CDP7851/AMG 785) |
postmenopausal osteoporosis |
3 |
Amgen (USA - CA) UCB (Belgium) |
Bone diseases |
2016-04-01
|
galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) |
acute myeloid leukemia |
1-2 |
SELLAS Life Sciences (Switzerland) |
Cancer - Oncology |
2016-04-01
|
binimetinib (MEK162) |
recurrent low-grade serous ovarian cancer (LGSOC) |
3 |
Array BioPharma (USA) Novartis (Switzerland) |
Cancer - Oncology - Rare diseases |
2016-03-31
|
Resunab™ (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid |
systemic lupus erythematosus |
|
Corbus Pharmaceuticals (USA - MA) |
Autoimmune diseases |
2016-03-31
|
Aplidin® (plitidepsin) in combination with dexamethasone |
relapsed/refractory multiple myeloma |
3 |
PharmaMar (Spain) |
Cancer - Oncology - Rare diseases |
2016-03-30
|
aramchol |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Galmed Pharmaceuticals (Israel) |
Hepatic diseases - Liver diseases |
2016-03-30
|
Docecal® (docetaxel) |
|
|
Oasmia Pharmaceutical (Sweden) |
Cancer - Oncology |
2016-03-29
|
INO-3112 |
locally advanced stage cervical cancer |
2 |
Inovio Pharmaceuticals (USA - PA) European Organization for Research and Treatment of Cancer (EORTC) |
Cancer - Oncology |
2016-03-29
|
dusquetide (SGX942) |
|
preclinical |
Soligenix (USA - NJ) |
Infectious diseases - Immunological diseases - Inflammatory diseases |
2016-03-24
|
APG101 (asunercept) |
myelodysplastic syndromes (MDS) |
preclinical |
Apogenix (Germany) |
Cancer - Oncology |
2016-03-24
|
Cimzia® (certolizumab pegol) |
rheumatoid arthritis |
4 |
UCB (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-03-24
|
epacadostat and CRS-207 |
platinum-resistant ovarian cancer, platinum-resistant fallopian cancer, platinum-resistant peritoneal cancer, |
1-2 |
Aduro Biotech (USA - CA) Incyte (USA - DE) |
Cancer - Oncology |
2016-03-24
|
Xtandi® (enzalutamide) |
metastatic hormone sensitive prostate cancer (mHSPC) |
3 |
Medivation (USA - CA) Astellas (Japan) |
Cancer - Oncology |
2016-03-24
|
SB8 (biosimilar version of bevacizumab - Avastin®) |
non-small cell lung cancer (NSCLC) |
3 |
Samsung Bioepis (Republic of Korea) |
Cancer - Oncology |
2016-03-23
|
BL-8040 |
mobilization and collection of bone marrow stem cells from the peripheral blood circulation |
2 |
BioLineRx (Israel) |
Transplantation |
2016-03-23
|
tasquinimod |
multiple myeloma |
1 |
Active Biotech (Sweden) |
Cancer - Oncology |